Fred Eshelman is the founder of Eshelman Ventures, LLC an investment company primarily interested in healthcare companies. Previously he founded and served as Chair/CEO of Pharmaceutical Product Development (PPDI) prior to the sale of the company to private equity interests. After PPD he served as founding chairman and largest shareholder of Furiex Pharmaceuticals (FURX), a company which in-licensed and rapidly developed new medicines. Furiex was sold to Forest Labs/Actavis in 2014. His career has also included positions as SVP development and board member of the former Glaxo, Inc., as well as management positions with Beecham Laboratories and Boehringer Mannheim Pharmaceuticals. He is currently chairman of several biotechs, and previously was chair of The Medicines Company (MDCO) and was on the board of Bausch Health (BHC). Eshelman has served on the executive committee of the Medical Foundation of NC, and was appointed by the NC General Assembly to serve on the Board of Governors for the state’s multi-campus university system (chair of audit committee), as well as the NC Biotechnology Center. In addition he chairs the board of visitors for the School of Pharmacy at UNC-CH. The School was named the UNC Eshelman School of Pharmacy in recognition of his many contributions to the school and the profession. US News & World Report named the School #1 in the US.
He has received many awards including the Davie and Distinguished Service Awards from UNC, outstanding alumnus from both the UNC and U. Cincinnati schools of pharmacy, Life Science Leadership Award (CED) and the NC Biotech Hall of Fame. Eshelman received the doctor of pharmacy from the U. of Cincinnati, completed a residency at Cincinnati General Hospital, and a BS Pharm from UNC-CH. He completed the OPM program at Harvard Business School. Eshelman also received an honorary doctor of science from UNC-CH.